Moreover, the data suggest that cotreatment with αPD-1 immunotherapy and either of the tellurium compounds may further increase CD8+ T-cell efficacy in ablating tumor cells, resulting in decreased tumor volume in a synergistic manner. The gene discussed is CD8A; the disease is neoplasm.